Inhibrx Biosciences Inc. reported a net loss of $35.3 million, or $2.28 per share, basic and diluted, for the third quarter of 2025, compared to a net loss of $43.9 million, or $2.84 per share, for the same period in 2024. Research and development expenses were $28.5 million, down from $38.9 million in the third quarter of 2024, primarily due to decreased process development, manufacturing activities, and lower personnel-related expenses. Cash and cash equivalents totaled $153.1 million as of September 30, 2025, compared to $186.6 million as of June 30, 2025. Other expense was $1.4 million, versus other income of $2.9 million in the same period last year, mainly due to interest expense on outstanding debt. During the period, Inhibrx announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and interim data from expansion cohorts in colorectal cancer and Ewing sarcoma. The company plans to submit a biologics license application for ozekibart to the FDA in the second quarter of 2026.